Does the media refer more to KYMR or ONC?

In the previous week, BeOne Medicines had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Kymera Therapeutics. BeOne Medicines' average media sentiment score of 0.51 beat Kymera Therapeutics' score of 0.35 indicating that BeOne Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BeOne Medicines 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MRNA or KYMR?

In the previous week, Moderna had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Moderna and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.35 beat Moderna's score of 0.22 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ROIV or KYMR?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.17 beat Kymera Therapeutics' score of 0.35 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is KYMR or INSM more profitable?

Insmed has a net margin of -144.44% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Kymera Therapeutics -611.94% -24.71% -22.05% Insmed -144.44% -130.11% -51.57%

Does the media favor KYMR or INSM?

In the previous week, Insmed had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Insmed and 8 mentions for Kymera Therapeutics. Insmed's average media sentiment score of 0.98 beat Kymera Therapeutics' score of 0.35 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 8 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kymera Therapeutics (KYMR) Competitors

$115.77 +1.78 (+1.56%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$115.84 +0.06 (+0.06%)

As of 07/17/2026 04:15 PM Eastern

Compare

KYMR vs. TEVA, ONC, MRNA, ROIV, and INSM

Should you buy Kymera Therapeutics stock or one of its competitors? MarketBeat compares Kymera Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Kymera Therapeutics include Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Kymera Therapeutics compare to Teva Pharmaceutical Industries?

Kymera Therapeutics (NASDAQ:KYMR) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Teva Pharmaceutical Industries has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A
Teva Pharmaceutical Industries	$17.26B	2.13	$1.41B	$1.33	24.06

Kymera Therapeutics has a beta of 1.95, suggesting that its share price is 95% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

Kymera Therapeutics presently has a consensus price target of $122.64, indicating a potential upside of 5.93%. Teva Pharmaceutical Industries has a consensus price target of $41.78, indicating a potential upside of 30.57%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Kymera Therapeutics' net margin of -611.94%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 9 more articles in the media than Kymera Therapeutics. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 8 mentions for Kymera Therapeutics. Teva Pharmaceutical Industries' average media sentiment score of 1.45 beat Kymera Therapeutics' score of 0.35 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	15 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Teva Pharmaceutical Industries beats Kymera Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to BeOne Medicines?

Kymera Therapeutics (NASDAQ:KYMR) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

In the previous week, BeOne Medicines had 5 more articles in the media than Kymera Therapeutics. MarketBeat recorded 13 mentions for BeOne Medicines and 8 mentions for Kymera Therapeutics. BeOne Medicines' average media sentiment score of 0.51 beat Kymera Therapeutics' score of 0.35 indicating that BeOne Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BeOne Medicines	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A
BeOne Medicines	$5.74B	5.97	$286.93M	$4.47	69.80

BeOne Medicines has a net margin of 8.94% compared to Kymera Therapeutics' net margin of -611.94%. BeOne Medicines' return on equity of 12.06% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
BeOne Medicines	8.94%	12.06%	6.69%

48.5% of BeOne Medicines shares are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by insiders. Comparatively, 6.2% of BeOne Medicines shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kymera Therapeutics has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Kymera Therapeutics currently has a consensus price target of $122.64, indicating a potential upside of 5.93%. BeOne Medicines has a consensus price target of $390.92, indicating a potential upside of 25.29%. Given BeOne Medicines' higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

BeOne Medicines beats Kymera Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Kymera Therapeutics compare to Moderna?

Moderna (NASDAQ:MRNA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Moderna currently has a consensus price target of $38.27, indicating a potential downside of 38.10%. Kymera Therapeutics has a consensus price target of $122.64, indicating a potential upside of 5.93%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Kymera Therapeutics is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	5 Sell rating(s)	10 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.82
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86

Moderna has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

In the previous week, Moderna had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 11 mentions for Moderna and 8 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.35 beat Moderna's score of 0.22 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.3% of Moderna shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Moderna has a net margin of -143.55% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-143.55%	-26.64%	-19.32%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Kymera Therapeutics has lower revenue, but higher earnings than Moderna. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$2.20B	11.13	-$2.82B	-$8.15	N/A
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Moderna on 10 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

64.8% of Roivant Sciences shares are held by institutional investors. 10.8% of Roivant Sciences shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Roivant Sciences has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Kymera Therapeutics has a net margin of -611.94% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Kymera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 2 more articles in the media than Roivant Sciences. MarketBeat recorded 8 mentions for Kymera Therapeutics and 6 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.17 beat Kymera Therapeutics' score of 0.35 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Roivant Sciences currently has a consensus target price of $33.59, suggesting a potential downside of 2.66%. Kymera Therapeutics has a consensus target price of $122.64, suggesting a potential upside of 5.93%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86

Roivant Sciences has higher earnings, but lower revenue than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,005.09	-$299.77M	-$0.60	N/A
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A

Summary

Kymera Therapeutics beats Roivant Sciences on 9 of the 16 factors compared between the two stocks.

How does Kymera Therapeutics compare to Insmed?

Kymera Therapeutics (NASDAQ:KYMR) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Kymera Therapeutics presently has a consensus target price of $122.64, suggesting a potential upside of 5.93%. Insmed has a consensus target price of $211.05, suggesting a potential upside of 94.84%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.86
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96

Kymera Therapeutics has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Insmed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market.

Insmed has a net margin of -144.44% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Insmed	-144.44%	-130.11%	-51.57%

In the previous week, Insmed had 7 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Insmed and 8 mentions for Kymera Therapeutics. Insmed's average media sentiment score of 0.98 beat Kymera Therapeutics' score of 0.35 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kymera Therapeutics has higher earnings, but lower revenue than Insmed. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$51.48M	185.00	-$311.35M	-$3.57	N/A
Insmed	$819.56M	28.65	-$1.28B	-$5.75	N/A

Summary

Insmed beats Kymera Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KYMR vs. The Competition

Export

Metric	Kymera Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.52B	$3.69B	$6.87B	$12.28B
Dividend Yield	N/A	2.17%	2.67%	9.34%
P/E Ratio	-32.43	21.03	27.25	23.92
Price / Sales	185.00	177.66	517.85	89.30
Price / Cash	N/A	154.08	52.99	60.41
Price / Book	5.96	8.26	10.69	6.18
Net Income	-$311.35M	$23.83M	$3.59B	$332.29M
7 Day Performance	-3.00%	-3.47%	-2.20%	-2.05%
1 Month Performance	28.02%	2.69%	1.63%	-2.18%
1 Year Performance	150.69%	45.93%	25.64%	17.67%

Kymera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KYMR Kymera Therapeutics	1.4718 of 5 stars	$115.77 +1.6%	$122.64 +5.9%	+150.7%	$9.52B	$51.48M	N/A	170	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.81 of 5 stars	$31.87 -1.0%	$41.78 +31.1%	+99.0%	$36.67B	$17.26B	23.98	33,950	Positive News
ONC BeOne Medicines	4.6913 of 5 stars	$304.87 +0.3%	$390.92 +28.2%	+5.9%	$33.48B	$5.34B	68.26	12,000	News Coverage Analyst Forecast Insider Trade
MRNA Moderna	1.7429 of 5 stars	$66.46 -0.8%	$38.27 -42.4%	+97.8%	$26.36B	$1.94B	N/A	4,700	Gap Down
ROIV Roivant Sciences	1.8376 of 5 stars	$34.87 +1.0%	$33.59 -3.7%	+201.7%	$25.08B	$8.26M	N/A	860	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KYMR) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kymera Therapeutics (KYMR) Competitors

KYMR vs. TEVA, ONC, MRNA, ROIV, and INSM

How does Kymera Therapeutics compare to Teva Pharmaceutical Industries?

Summary

How does Kymera Therapeutics compare to BeOne Medicines?

Summary

How does Kymera Therapeutics compare to Moderna?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Summary

How does Kymera Therapeutics compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kymera Therapeutics (KYMR) Competitors

KYMR vs. TEVA, ONC, MRNA, ROIV, and INSM

How does Kymera Therapeutics compare to Teva Pharmaceutical Industries?

Which has stronger valuation & earnings, KYMR or TEVA?

Which has more volatility and risk, KYMR or TEVA?

Do analysts recommend KYMR or TEVA?

Do insiders and institutionals have more ownership in KYMR or TEVA?

Is KYMR or TEVA more profitable?

Does the media refer more to KYMR or TEVA?

Summary

How does Kymera Therapeutics compare to BeOne Medicines?

Does the media refer more to KYMR or ONC?

Which has better valuation and earnings, KYMR or ONC?

Is KYMR or ONC more profitable?

Do insiders & institutionals believe in KYMR or ONC?

Which has more risk & volatility, KYMR or ONC?

Do analysts prefer KYMR or ONC?

Summary

How does Kymera Therapeutics compare to Moderna?

Do analysts rate MRNA or KYMR?

Which has more volatility & risk, MRNA or KYMR?

Does the media favor MRNA or KYMR?

Do institutionals and insiders believe in MRNA or KYMR?

Is MRNA or KYMR more profitable?

Which has stronger earnings and valuation, MRNA or KYMR?

Summary

How does Kymera Therapeutics compare to Roivant Sciences?

Do institutionals & insiders believe in ROIV or KYMR?

Which has more risk & volatility, ROIV or KYMR?

Is ROIV or KYMR more profitable?

Does the media prefer ROIV or KYMR?

Do analysts prefer ROIV or KYMR?

Which has stronger valuation & earnings, ROIV or KYMR?

Summary

How does Kymera Therapeutics compare to Insmed?

Do analysts prefer KYMR or INSM?

Which has more risk & volatility, KYMR or INSM?

Is KYMR or INSM more profitable?

Does the media favor KYMR or INSM?

Which has better earnings & valuation, KYMR or INSM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KYMR vs. The Competition

Kymera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools